Importance of Understanding Immune Reaction and Pharmacokinetic on the Development of Liposomal DDS Formulations

DOI Web Site Web Site 16 References Open Access
  • ANDO Hidenori
    Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
  • SHIMIZU Taro
    Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
  • ISHIDA Tatsuhiro
    Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University

Bibliographic Information

Other Title
  • リポソームDDS製剤開発における免疫系の制御と動態解析の重要性
  • リポソーム DDS セイザイ カイハツ ニ オケル メンエキケイ ノ セイギョ ト ドウタイ カイセキ ノ ジュウヨウセイ

Search this article

Description

<p>Liposome is one of the fascinating drug delivery carrier. Several liposome formulations have been approved for clinical use. Most of the anticancer drugs, including the liposome formulations, need to be passed through the screening steps, which catch up the candidates with the highest antitumor effect, and then undergoing to the preclinical and clinical phases. However, the development process is slowed or even sometime prevented by the loss of understanding of pharmacokinetics of encapsulated drugs, the tumor immune modulation by liposome formulation, and the adverse reactions via induction of the specific antibodies to DDS carriers. In this article, we overview these issues we should pay further attention to develop liposomal formulation of anticancer drugs.</p>

Journal

  • Oleoscience

    Oleoscience 20 (2), 71-76, 2020

    Japan Oil Chemists' Society

References(16)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top